E.U. committee rebuffs Avastin for brain cancer; Indian court lifts block on Sun-Ranbaxy deal;

@FiercePharma: Top-read special report over the long weekend: The top 10 pharma companies by 2013 revenue. Feature | Follow @FiercePharma

@TracyStaton: ICYMI, FiercePharma's top weekend news: FDA-nixed diabetes med from Lilly, Boehringer faces rough path to stardom. Article | Follow @TracyStaton

@EricPFierce: ICYMI from FiercePharmaManufacturing: More woes for Indian drugmakers. Teva recalls 40,000 bottles of drugs made by Emcure over testing problems. Story | Follow @EricPFierce

@CarlyHFierce: Allergan investors want up to $200 per share from Valeant. More | Follow @CarlyHFierce

> European regulators rejected Roche's ($RHHBY) Avastin as a treatment for the form of brain cancer known as glioblastoma, saying supporting clinical data wasn't convincing. Report

> Sun Pharmaceutical is free to proceed with its buyout of its Indian generics rival, Ranbaxy Laboratories, after a domestic court lifted a stay on the deal. Report (sub. req.)

> Roche ($RHHBY) expects its diagnostic division to grow in the U.S. faster than the rest of the market, despite cuts to Medicare reimbursement rates. Report

> Sanofi ($SNY) inked a deal to promote its generics portfolio in the Middle East via a Dubai Investment pharmaceutical subsidiary, Globalpharma. Report

> The FDA approved a new drug for acute bacterial skin infections, Dalvance, made by Durata Therapeutics. Release | Report

> Inovio's ($INO) animal health subsidiary VGX has transferred its exclusive license with Inovio of its growth hormone-releasing hormone (GHRH) and animal DNA vaccines to South Korea's Plumbline Life Sciences. Release

Medical Device News

@FierceMedDev: Roche said its surging Dx division doesn't need price reductions. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: My Uncle says "loose connection" causes most household mechanical snafus (and device recalls too, I have learned). FDA alert | Article | Follow @VarunSaxena2

@MichaelGFierce: ICYMI from FierceDrugDelivery: Smallest, fastest nanomotor moves drugs and releases them on demand. Article | Follow @MichaelGFierce

@EmilyWFierce: Sequencing the of brewing yeasts could help brewers craft new flavors of beer. NYT story | Follow @EmilyWFierce

> Sleep apnea startup banks $11M for ultrasmall device development. News

> Scientists weigh in on neuromodulation devices to treat chronic inflammatory diseases. Story

> Johnson & Johnson medical device presence growing in China. Report

Biotech News

@FierceBiotech: Thursday, @JohnCFierce and David Porter of @PennMedicine will chat, break down #ASCO2014. Follow #FierceASCO at 3:30 EST. Sponsor: @Covance. | Follow @FierceBiotech

@JohnCFierce: PhIII flop for top Boston cancer stem cell program batters Dainippon Sumitomo. Article | Follow @JohnCFierce

@DamianFierce: Allergan with a very thorough Ethering of Vertex's "anemic growth driven by ... unsustainable price increases--not volume." More (PDF) | Follow @DamianFierce

@EmilyMFierce: Antigen discovery could advance malaria vaccine. Story | Follow @EmilyMFierce

> Analysis: A weakened Pfizer signals that it's prepped to wheel and deal. Editor's corner

> Bristol-Myers adds a $1.24B deal plus partnership in immuno-oncology deal frenzy. More

> Pfizer to AstraZeneca: Say goodbye to our $120B offer. Report

CRO News

> CRO Rho mounts a talent search as contracts come in. Item

> Newly merged U.K. CRO sets sail in the Cambridge biopharma hub. Report

> Clinverse partners up to bolster its trial payment software. More

> Medidata teams up with Big Pharma supergroup to de-risk trials. Article

> Parexel zeroes in on adaptive trials with its latest eClinical move. Story

Biotech IT News

> Facebook, Twitter and YouTube targeted in fake drug crackdown. Item

> Medidata, Parexel jostle for position in risk-based monitoring market. More

> Broad moves into new digs designed to encourage serendipitous discoveries. Report

> Pharma's cloud doubts prompt tech firms to add local alternatives. Article

> Takeda inks $400M IT services deal with Wipro. Story

Biotech Research News

> Database IDs new uses for existing drugs. Item

> Neurotrope, Stanford partner to treat neurological disorders with bryostatins. Report

> Antisense compound may provide new Alzheimer's treatment. Story

> Preventing biofilm formation could help fight antibiotic resistance. Article

> Antigen discovery could advance malaria vaccine. More

Pharma Manufacturing News

> Continuous manufacturing maintains slow creep toward the mainstream. Item

> WHO's links to ICH under fire amid efforts to strengthen manufacturing regulations. Report

> SeQuent continues to build Indian API assets with Arvee acquisition. Story

> Fresenius recalls hemodialysis liquid after bacteria discovery. More

> Report: FDA to inspect more Sun plants in the next few weeks. Article

And Finally... Could the Novartis ($NVS) multiple sclerosis pill Gilenya help treat PTSD? It helped traumatized mice, a new study shows. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.